Thomas Jefferson University
Sidney Kimmel Medical College
Department of Medicine

Research Activity

Recent Publications

Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial

Erratum to: Musculoskeletal manifestations of primary hyperparathyroidism (Clinical Rheumatology, (2016), 35, 12, (3081-3087), 10.1007/s10067-016-3450-3)

Follicular thyroid cancer with hematogenous osseous metastasis

The "indeterminate" thyroid FNA: What additional genomic testing can help differentiate malignancy risk?

Diagnosis and management of thyroid lymphoma

Evaluation and management of medullary thyroid cancer

Insulin degludec 200 Units/mL is associated with lower injection frequency and improved patient-reported outcomes compared with insulin glargine 100 Units/mL in patients with type 2 diabetes requiring high-dose insulin

Musculoskeletal manifestations of primary hyperparathyroidism

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial

SGLT2 inhibitors

Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: A 24-week, multicenter, randomized, double-blind, placebo-controlled study

Dapagliflozin in type 2 diabetes: Effectiveness across the spectrum of disease and over time

An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients

Dapagliflozin is effective as add-on therapy to sitagliptin with or withoutmetformin: A 24-Week, multicenter, randomized, double-blind, placebo-controlled study

SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: A new approach to an old problem

Comment and response to: Dapagliflozin-do we need it registered for type 2 diabetes?

The emerging role of oxylipins in thrombosis and diabetes

Diabetes, antidiabetic drugs, and cancer: Separating background risk from iatrogenesis

Is above age 45 appropriate for upstaging well-differentiated papillary thyroid cancer?

Ramadan: Type 2 diabetes and risk of hypoglycaemia